Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Melatonin treatment for rhythm disorder

M Kato1, N Kajimura, M Sekimoto

  • 1National Center Hospital for Mental, Nervous and Muscular Disorders, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.

Psychiatry and Clinical Neurosciences
|June 17, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acquisition of interleukin-3 independence in FDC-P2 cells after transfection with the activated c-H-ras gene using a bovine papillomavirus-based plasmid vector.

Blood·1992
Same author

Effects of Ca2+ antagonists and antiepileptics on tetrodotoxin-sensitive Ca(2+)-conducting channels in isolated rat hippocampal CA1 neurons.

Neuroscience letters·1992
Same author

Novel phenylketonuria mutation detected by analysis of ectopically transcribed phenylalanine hydroxylase mRNA from lymphoblast.

Lancet (London, England)·1992
Same author

Fluorescent probe-labeled lipid microsphere uptake by human endothelial cells: a flow cytometric study.

Japanese journal of pharmacology·1992
Same author

[Studies on IFN-gamma production by peripheral blood mononuclear cells cultured with Candida antigen in asthmatics].

Arerugi = [Allergy]·1992
Same author

Site-directed mutagenesis of amino acid residues involved in the glutathione binding of human glutathione S-transferase P1-1.

Journal of biochemistry·1992

Melatonin treatment showed varied effects for non-24-hour sleep-wake syndrome. It improved sleep onset/offset in one patient and reset circadian rhythm in another, though the latter effect was temporary.

Area of Science:

  • Chronobiology
  • Sleep Medicine
  • Neuropharmacology

Background:

  • Non-24-hour sleep-wake syndrome (Non-24) is a circadian rhythm disorder often resistant to standard treatments.
  • Investigating novel therapeutic strategies is crucial for managing this condition.

Observation:

  • Two patients with Non-24, unresponsive to vitamin B12, bright light therapy, or hypnotics, were treated with melatonin.
  • Patient 1 received 5-10 mg melatonin, improving sleep onset and offset but not circadian rhythm.
  • Patient 2 received 3 mg melatonin, successfully shifting a free-running rhythm to a delayed sleep phase pattern.

Findings:

  • Melatonin demonstrated dual potential actions: sleep induction in one patient and circadian phase-setting in another.
  • The phase-setting effect in the second patient was transient, as re-administration after a drug-free period failed to restore the rhythm.

Related Experiment Videos

Implications:

  • Melatonin may serve as a sleep-inducing agent or a transient circadian phase-setter in Non-24.
  • Further research is needed to understand the mechanisms and long-term efficacy of melatonin in circadian rhythm disorders.